Study on Anakinra’s Effects on Joint Damage and Blood Glucose Levels

Overview of Rheumatoid Arthritis

A recent study explored the potential benefits of anakinra for patients suffering from both rheumatoid arthritis (RA) and type 2 diabetes, particularly focusing on joint damage and blood glucose levels. RA is a chronic condition that impacts the joints, resulting from the immune system mistakenly attacking them. This leads to symptoms such as pain, swelling, and stiffness. If left untreated, RA can result in significant joint damage, potentially necessitating joint replacement surgery. The condition typically affects both sides of the body symmetrically, with the hands and feet being the most commonly involved joints. Additionally, RA can affect other organs, including the lungs, heart, and eyes. According to the Rheumatoid Arthritis Network, approximately one percent of the global population is impacted by this disease. Patients with RA also face increased risks of cardiovascular disease, diabetes, and hypertension.

The Role of Biologics in Treatment

The exact cause of RA remains unclear, and there is currently no known cure. However, treatments such as biologics play a crucial role in managing symptoms and improving patients’ quality of life. Biologics like anakinra, which are derived from human proteins, have been effective in reducing joint damage and slowing disease progression. Anakinra is administered via subcutaneous injection and may take three to six months for patients to experience its full effects.

Investigating Blood Glucose Levels

Research has indicated a potential link between RA and increased blood glucose levels, which is characteristic of type 2 diabetes. A recent study published in PLOS Medicine aimed to determine whether anakinra could alleviate joint damage while also lowering blood glucose levels in patients with both RA and type 2 diabetes. This study compared anakinra with tumor necrosis factor inhibitors (TNFis), which are commonly used to alleviate pain and swelling in RA patients.

Study Design and Findings

The study involved 39 participants diagnosed with RA and type 2 diabetes, recruited from twelve rheumatologic centers in Italy between 2013 and 2016. Participants were randomly assigned to receive either anakinra or TNFis over a six-month treatment period in an open-label trial, where participants were aware of their assigned treatments.

The results indicated a significant reduction in blood glucose levels among participants treated with anakinra compared to those receiving TNFis. Both treatment groups exhibited notable improvements in RA symptoms. Furthermore, the researchers identified a correlation between the reduction in blood glucose levels and the alleviation of RA symptoms among those treated with anakinra. Importantly, there were no serious adverse reactions reported during the study.

Future Research Directions

The study’s findings suggest that anakinra could be a viable treatment option for patients with both rheumatoid arthritis and type 2 diabetes. However, the researchers emphasize the need for further studies to evaluate the efficacy of anakinra as a treatment for both conditions and to investigate its implications for the risk of developing cardiovascular diseases.

References

Ruscitti P, Masedu F, Alvaro S, Airò P, Battafarano N, Cantarini L, et al. (2019). Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLOS Med. doi: 10.1371/journal.pmed.1002901
What is rheumatoid arthritis? https://www.medicalnewstoday.com/articles/323361.php
Anakinra. https://arthritis.ca/treatment/medication/medication-reference-guide/medications/anakinra
Image by IAOM-US from Pixabay